Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › Apollomics Advances Phase I/II SPARTA Trial for C-MET Inhibitor in MET-Altered Tumors

Apollomics Advances Phase I/II SPARTA Trial for C-MET Inhibitor in MET-Altered Tumors

May 21, 2020
|
staff reporter

NEW YORK – Apollomics has launched the Phase II portion of the Phase I/II SPARTA trial for its investigational c-MET inhibitor APL-101, which will enroll patients with different tumors and MET alterations.   

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jul
16
Featured Webinar

Exploring Tumor Tissue Architecture and Immune Response with Digital Spatial Profiling

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In Cancer

  1. Case Study Supports Potential First-Line Use of Vitrakvi in NTRK Fusion-Positive Glioblastoma

    Premium

  2. Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis

  3. Presence of cfDNA, CTCs Predicts Recurrence in Triple-Negative Breast Cancer

  4. Prostate Cancer Genomics Study IDs PARP Inhibitors as Potentially Beneficial to Black Men

  5. PARP Inhibitor Lynparza Receives EU Approval for Germline BRCA-Mutated Pancreatic Cancer

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.